II. Indications
III. Contraindications
- See Angiotensin Receptor Blocker
- Glomerular Filtration Rate (GFR) <30 ml/min/1.73m2
IV. Mechanism
V. Dosing: Adults
-
Hypertension
- Start 16 mg orally daily
- Start 8 mg daily with concurrent Diuretic, elderly or GFR 30 to 60 ml/min/1.73m2
- Maximum 32 mg/day
- Start 16 mg orally daily
-
Congestive Heart Failure
- Start 4 mg orally daily
- May double dose every 2 weeks as needed
- Maximum 32 mg/day
VI. Dosing: Children
-
Hypertension
- Age 1 to 5 years
- Start 0.2 mg/kg oral suspension
- Target 0.05 to 0.4 mg/kg/day
- Age 6 to 16 years and weight <50 kg
- Start 4 to 8 mg/day
- Target 4 to 16 mg/day
- Age 6 to 16 years and weight >50 kg
- Start 8 to 16 mg/day
- Target 4 to 32 mg/day
- Maximum: 0.4 mg/kg/day up to 32 mg
- Age 1 to 5 years
VII. Adverse Effects
VIII. Safety
- See Angiotensin Receptor Blocker
- Pregnancy Category X
- Unknown Safety in Lactation
IX. Resources
X. References
- (2018) Presc Lett, Resource #340901, Angiotensin Receptor Blocker (ARB) Antihypertensive Dose Comparison
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 66-7
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
candesartan (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CANDESARTAN CILEXETIL 16 MG TB | Generic | $0.79 each |
CANDESARTAN CILEXETIL 32 MG TB | Generic | $0.96 each |
CANDESARTAN CILEXETIL 4 MG TAB | Generic | $0.80 each |
CANDESARTAN CILEXETIL 8 MG TAB | Generic | $0.77 each |
CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB | Generic | $1.12 each |
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB | Generic | $1.76 each |
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB | Generic | $1.47 each |
Ontology: candesartan (C0717550)
Definition (NCI) | A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. Candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081643 |
SnomedCT | 108587008, 372512008 |
LNC | LP171390-0 |
English | 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole, 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic Acid, candesartan [Chemical/Ingredient], CANDESARTAN, candesartan, Candesartan (product), Candesartan (substance), Candesartan |
Spanish | candesartano (sustancia), candesartano, candesartán (producto), candesartán (sustancia), candesartán |
Ontology: Atacand (C0718711)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C077793 |
English | Atacand, atacand, blopress, Amias, Blopress, Astra brand of candesartan cilexetil, AstraZeneca brand of candesartan cilexetil, Kenzen, Promed brand of candesartan cilexetil, Takeda brand of candesartan cilexetil |